Fahy MR, Kelly ME, Power Foley M, Nugent TS, Shields CJ, Winter DC. The role of intraoperative radiotherapy in advanced rectal cancer: a meta-analysis. Colorectal Dis. 2021;23:1998–2006. https://doi.org/10.1111/CODI.15698.

Article  PubMed  Google Scholar 

Arshad M, Al-Hallaq H, Polite BN, Shogan BD, Hyman N, Liauw SL. Intra-operative radiation therapy for colorectal or anal cancer at risk for margin-positive resection: initial results of a single-institution registry. Ann Surg Oncol. 2023;30:325–32. https://doi.org/10.1245/S10434-022-12564-3.

Article  PubMed  Google Scholar 

Ng JC, Sassun R, Sileo A, Violante T, Brady JT, DeLeon MF, et al. Real-world clinical outcomes of total neoadjuvant therapy followed by total mesorectal excision for locally advanced rectal cancer at a high-volume institution. Eur J Surg Oncol. 2025;110181. https://doi.org/10.1016/J.EJSO.2025.110181.

Article  PubMed  Google Scholar 

Storli PE, Dille-Amdam RG, Skjærseth GH, Gran MV, Myklebust TÅ, Grønbech JE, et al. Cumulative incidence of first recurrence after curative treatment of stage I-III colorectal cancer. Competing risk analyses of temporal and anatomic patterns. Acta Oncol. 2023;62:1822–30. https://doi.org/10.1080/0284186X.2023.2269644.

Article  CAS  PubMed  Google Scholar 

Fleshman J, Branda ME, Sargent DJ, Boller AM, George VV, Abbas MA, et al. Disease-free survival and local recurrence for laparoscopic resection compared with open resection of stage II to III rectal cancer: follow-up results of the ACOSOG Z6051 randomized controlled trial. Ann Surg. 2019;269:589–95. https://doi.org/10.1097/SLA.0000000000003002.

Article  PubMed  Google Scholar 

You YN, Hardiman KM, Bafford A, Poylin V, Francone TD, Davis K, et al. The American Society of Colon and Rectal Surgeons Clinical Practice Guidelines for the Management of Rectal Cancer. Dis Colon Rectum. 2020;63:1191–222. https://doi.org/10.1097/DCR.0000000000001762.

Article  PubMed  Google Scholar 

Park JS, Sakai Y, Simon NSM, Law WL, Kim HR, Oh JH, et al. Long-term survival and local relapse following surgery without radiotherapy for locally advanced upper rectal cancer: an international multi-institutional study. Medicine (Baltimore). 2016. https://doi.org/10.1097/MD.0000000000002990.

Article  PubMed  PubMed Central  Google Scholar 

Fossum CC, Alabbad JY, Romak LB, Hallemeier CL, Haddock MG, Huebner M, et al. The role of neoadjuvant radiotherapy for locally-advanced rectal cancer with resectable synchronous metastasis. J Gastrointest Oncol. 2017;8:650. https://doi.org/10.21037/JGO.2017.06.07.

Article  PubMed  PubMed Central  Google Scholar 

Ng JC, Sileo A, Sassun R, Aboelmaaty S, Violante T, Gomaa IA, et al. Predictors of pathologic non-response to neoadjuvant approaches in locally advanced rectal cancer. Ann Surg Oncol. 2025. https://doi.org/10.1245/S10434-025-16962-1.

Article  PubMed  PubMed Central  Google Scholar 

Glimelius B, Tiret E, Cervantes A, Arnold D. Rectal cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2013;24. https://doi.org/10.1093/ANNONC/MDT240. Suppl 6.

Gomaa IA, Aboelmaaty S, Sassun R, Sileo A, Ng JC, Keshk NO, et al. Downstaged lateral pelvic lymph nodes require no resection after neoadjuvant therapy and total mesorectal excision. J Gastrointest Surg. 2025;29:102206. https://doi.org/10.1016/j.gassur.2025.102206.

Article  PubMed  Google Scholar 

Chow OS, Kuk D, Keskin M, Smith JJ, Camacho N, Pelossof R, et al. KRAS and combined KRAS/TP53 mutations in locally advanced rectal cancer are independently associated with decreased response to neoadjuvant therapy. Ann Surg Oncol. 2016;23:2548–55. https://doi.org/10.1245/S10434-016-5205-4.

Article  PubMed  PubMed Central  Google Scholar 

Duldulao MP, Lee W, Nelson RA, Li W, Chen Z, Kim J, et al. Mutations in specific codons of the KRAS oncogene are associated with variable resistance to neoadjuvant chemoradiation therapy in patients with rectal adenocarcinoma. Ann Surg Oncol. 2013;20:2166–71. https://doi.org/10.1245/S10434-013-2910-0.

Article  PubMed  PubMed Central  Google Scholar 

Swets M, Graham Martinez C, van Vliet S, van Tilburg A, Gelderblom H, Marijnen CAM, et al. Microsatellite instability in rectal cancer: what does it mean? A study of two randomized trials and a systematic review of the literature. Histopathology. 2022;81:352–62. https://doi.org/10.1111/HIS.14710.

Article  PubMed  PubMed Central  Google Scholar 

He Y, Van’t Veer LJ, Mikolajewska-Hanclich I, Van Velthuysen MLF, Zeestraten ECM, Nagtegaal ID, et al. PIK3CA mutations predict local recurrences in rectal cancer patients. Clin Cancer Res. 2009;15:6956–62. https://doi.org/10.1158/1078-0432.CCR-09-1165.

Article  CAS  PubMed  Google Scholar 

Kohonen-Corish MRJ, Tseung J, Chan C, Currey N, Dent OF, Clarke S, et al. KRAS mutations and CDKN2A promoter methylation show an interactive adverse effect on survival and predict recurrence of rectal cancer. Int J Cancer. 2014;134:2820–8. https://doi.org/10.1002/IJC.28619.

Article  CAS  PubMed  Google Scholar 

Cuschieri S. The STROBE guidelines. Saudi J Anaesth. 2019;13:S31–4. https://doi.org/10.4103/SJA.SJA_543_18.

Article  PubMed  PubMed Central  Google Scholar 

Benson AB, Venook AP, Al-Hawary MM, Azad N, Chen YJ, Ciombor KK, et al. Rectal Cancer, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2022;20:1139–67. https://doi.org/10.6004/JNCCN.2022.0051.

Article  CAS  PubMed  Google Scholar 

Swartjes H, van Rees JM, van Erning FN, Verheij M, Verhoef C, de Wilt JHW, et al. Locally recurrent rectal cancer: toward a second chance at cure? A population-based, retrospective cohort study. Ann Surg Oncol. 2023;30:3915–24. https://doi.org/10.1245/S10434-023-13141-Y.

Article  PubMed  PubMed Central  Google Scholar 

Ng JC, Sassun R, Sileo A, Perry WRG, Mathis KL, Larson DW. Pathological staging predicts survival more accurately than clinical staging in locally advanced rectal cancer following total neoadjuvant therapy. Br J Surg. 2025. https://doi.org/10.1093/BJS/ZNAF034.

Article  PubMed  Google Scholar 

Syk E, Glimelius B, Nilsson PJ. Factors influencing local failure in rectal cancer: analysis of 2315 patients from a population-based series. Dis Colon Rectum. 2010;53:744–52. https://doi.org/10.1007/DCR.0B013E3181CF8841.

Article  CAS  PubMed  Google Scholar 

Xu Z, Bao M, Cai Q, Wang Q, Xing W, Liu Q. Optimization of treatment strategies based on preoperative imaging features and local recurrence areas for locally advanced lower rectal cancer after lateral pelvic lymph node dissection. Front Oncol. 2024. https://doi.org/10.3389/FONC.2023.1272808.

Article  PubMed  PubMed Central  Google Scholar 

Sileo A, Sassun R, Ng JC, Aboelmaaty S, Gomaa IA, Mari G, et al. Age matters: early-onset rectal cancer exhibits higher rates of pathological complete response: a retrospective analysis of the influence of young age on treatment success in stage II-III rectal cancer. Ann Surg Oncol. 2025. https://doi.org/10.1245/S10434-024-16773-W.

Article  PubMed  Google Scholar 

Gaedcke J, Grade M, Jung K, Schirmer M, Jo P, Obermeyer C, et al. KRAS and BRAF mutations in patients with rectal cancer treated with preoperative chemoradiotherapy. Radiother Oncol. 2010;94:76–81. https://doi.org/10.1016/J.RADONC.2009.10.001.

Article  CAS  PubMed  Google Scholar 

Aboelmaaty S, Gomaa IA, Sileo A, Sassun R, Ng JC, Keshk NO, et al. The impact of RAS/BRAF mutation on pathological complete response after total neoadjuvant therapy in rectal cancer. Ann Surg Oncol. 2025;32:7326–32. https://doi.org/10.1245/S10434-025-17804-W.

Article  PubMed  Google Scholar 

Zhou P, Goffredo P, Ginader T, Thompson D, Hrabe J, Gribovskaja-Rupp I, et al. Impact of KRAS status on tumor response and survival after neoadjuvant treatment of locally advanced rectal cancer. J Surg Oncol. 2021;123:278–85. https://doi.org/10.1002/JSO.26244.

Article  CAS  PubMed  Google Scholar 

Margonis GA, Amini N, Andreatos N, Sasaki K, McVey J, Mirza MB, et al. KRAS mutational status impacts pathologic response to pre-hepatectomy chemotherapy: a study from the International Genetic Consortium for Liver Metastases. HPB (Oxford). 2019;21:1527–34. https://doi.org/10.1016/J.HPB.2019.03.368.

Article  PubMed  Google Scholar 

Yu HA, Sima CS, Shen R, Kass S, Gainor J, Shaw A, et al. Prognostic impact of KRAS mutation subtypes in 677 patients with metastatic lung adenocarcinomas. J Thorac Oncol. 2015;10:431–7. https://doi.org/10.1097/JTO.0000000000000432.

Article  CAS  PubMed  PubMed Central  Google Scholar